Physician profile
Patrick J Bell
NPI 1013900612
$3,346.16
in general payments reported to CMS, 2019-2025
20 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $265 · 2021: $124 · 2022: $121 · 2023: $204 · 2024: $2,315 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,833 · Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,832.62 |
| Food and Beverage | $889.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,220.62 | 2024 | Cvi Contact Lens |
| Kala Pharmaceuticals, INC. | $138.39 | 2020-2021 | |
| Abbvie INC. | $134.64 | 2023-2025 | Durysta |
| Alimera Sciences, INC. | $117.20 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $108.55 | 2022-2025 | Miebo, Xipere, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $102.33 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $68.53 | 2025 | Yutiq |
| Aerie Pharmaceuticals, INC. | $65.70 | 2019-2020 | |
| Oyster Point Pharma, INC. | $47.37 | 2022-2023 | Tyrvaya |
| Astellas Pharma US INC | $45.53 | 2023-2024 | Izervay |
| Allergan, INC. | $43.14 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $40.19 | 2022-2023 | Xeomin |
| Tarsus Pharmaceuticals, INC. | $40.04 | 2025 | Xdemvy |
| Genentech USA, INC. | $37.98 | 2024-2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $32.57 | 2022-2023 | Cequa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.07 | 2020-2022 | |
| Biotissue Holdings INC. | $24.16 | 2020 | |
| Rayner Intraocular Lenses Limited | $19.99 | 2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Coherus Oncology, INC. | $19.13 | 2023 | |
| Beaver-Visitec International, INC. | $15.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.